Michael Raab is the President, Chief Executive Officer, and Director at Ardelyx, Inc., a biopharmaceutical company focused on developing innovative first-in-class medicines to enhance patient lives. With a robust background in the pharmaceutical industry, Raab has been instrumental in steering Ardelyx towards significant milestones. He joined Ardelyx in 2018 and has since led the company through critical phases of clinical development and commercialization. Under his leadership, Ardelyx successfully brought its first product, IBSRELA® (tenapanor), to market, marking a significant achievement in the treatment of irritable bowel syndrome with constipation (IBS-C). Before joining Ardelyx, Raab held several high-profile positions that equipped him with the expertise necessary to drive a biopharmaceutical company forward. He was the President and CEO of Puma Biotechnology, where he played a pivotal role in advancing the company's oncology drug development pipeline. Prior to that, Raab served as the Chief Executive Officer of Ambit Biosciences, leading the company until its acquisition by Daiichi Sankyo. His career also includes significant tenures at Biogen, where he served as Senior Vice President of the Neurology Business Unit, and at Genentech, where he was Vice President of Sales and Marketing. Raab's extensive experience in leadership roles within the biopharma sector has been crucial in shaping Ardelyx's strategic direction and operational success. As President and CEO of Ardelyx, Michael Raab is responsible for overseeing the company's overall strategy, operations, and growth. His leadership has been vital in navigating the complex landscape of drug development and regulatory approval. Raab's vision for Ardelyx is to continue expanding its portfolio of innovative treatments, with a focus on cardiorenal diseases and gastrointestinal disorders. His commitment to advancing patient care and his strategic acumen have positioned Ardelyx as a leader in the development of novel therapies, promising a bright future for the company under his guidance.